Table 3.
Associations between gene mutations and clinicpathological characteristics of patients.
KRAS | P -value | PIK3CA | P -value | BRAF | P -value | ||||
---|---|---|---|---|---|---|---|---|---|
Mutation | Wild type | Mutation | Wild type | Mutation | Wild type | ||||
n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | ||||
Gender | |||||||||
Male | 12 (60.0) | 318 (68.4) | 0.432 | 12 (66.7) | 318 (68.1) | 1.000 | 3 (50.0) | 327 (68.3) | 0.341 |
Female | 8 (40.0) | 147 (31.6) | 6 (33.3) | 149 (31.9) | 3 (50.0) | 152 (31.7) | |||
Age, years | |||||||||
<45 | 2 (10.0) | 57 (12.3) | 0.933 | 4 (22.2) | 55 (11.8) | 0.332 | 1 (16.7) | 58 (12.1) | 0.572 |
45-49 | 2 (10.0) | 40 (8.6) | 1 (5.6) | 41 (8.8) | 0 | 42 (8.8) | |||
50-70 | 13 (65.0) | 276 (59.4) | 10 (55.6) | 279 (59.7) | 5 (83.3) | 284 (59.3) | |||
≥70 | 3 (15.0) | 92 (19.7) | 3 (16.6) | 92 (19.7) | 0 | 95 (19.8) | |||
TNM stage | |||||||||
I | 1(5.0) | 67 (14.4) | 0.525 | 3 (16.7) | 65 (13.9) | 0.179 | 0 | 68 (14.2) | 0.009 |
II | 7 (35.0) | 94 (20.2) | 6 (33.3) | 95 (20.3) | 0 | 101 (21.1) | |||
III | 5 (25.0) | 189 (40.6) | 7 (38.9) | 187 (40.0) | 1 (16.7) | 193 (40.3) | |||
IV | 7 (35.0) | 115 (24.8 ) | 2 (11.1) | 120 (25.8) | 5 (83.3) | 117 (24.4) | |||
Tumor location | |||||||||
Upper | 7 ( 35.0) | 140 (30.1) | 0.646 | 5 (27.8) | 142 (30.4) | 0.634 | 3 (50.0) | 144 (30.1) | 0.937 |
Middle | 6 (30.0) | 85 (18.3) | 6 (33.3) | 85 (18.2) | 0 | 91 (19.0) | |||
Lower | 3 (15.0) | 198 (42.6) | 6 (33.3) | 195 (41.8) | 1 (16.7) | 200 (41.8) | |||
Residual gastric or total gastric | 4 (20.0) | 42 (9.0) | 1 (5.6) | 45 (9.6) | 2 (33.3) | 44 (9.1) | |||
Lymph node status | |||||||||
pN0 | 10 (50.0) | 138 ( 29.7) | 0.139 | 22.2(4) | 144 (30.8) | 0.556 | 0 | 148 (30.9) | 0.320 |
pN1 | 5 (25.0) | 132 ( 28.4) | 38.9(7) | 130 (27.8) | 3 (50.0) | 134 (28.0) | |||
pN2 | 2 (10.0) | 139 (29.9) | 16.7(3) | 138 (29.6) | 2 (33.3) | 139 (29.0) | |||
pN3a/b | 3 (15.0) | 56 (12.0) | 22.2(4) | 55 (11.8) | 1 (16.7) | 58 (12.1) |